# A Single-dose, Comparative Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fasting Conditions

> **NCT03573622** · PHASE1 · COMPLETED · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 62 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Anpl-one SR Tab. 300mg
- **DRUG:** Sarpodipil SR Tab. 300mg

## Key facts

- **NCT ID:** NCT03573622
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-31
- **Primary completion:** 2018-08-21
- **Final completion:** 2018-10-12
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2019-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03573622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03573622, "A Single-dose, Comparative Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fasting Conditions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03573622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*